Europe
AstraZeneca and Sanofi secured accelerated authorization for respiratory syncytial virus (RSV) antibody nirsevimab from the European Medicines Agency.
Public health officials begin to think we’ve turned the corner on the pandemic as new global cases drop 21% last week, the third consecutive week numbers and deaths have declined.
Robert LaCaze is taking over the reins of Mnemo Therapeutics with the goal of overcoming key challenges in CAR-T therapies and driving the company’s lead assets into the clinic.
Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders.
Proceeds will be used to assemble and develop a diversified pipeline of therapies to address sight-threatening illnesses.
With IND approval, the therapeutics have become the first LBPs for Parkinson’s disease cleared by the FDA.
Synairgen watched its stock plummet 85% after reporting disappointing Phase III results for its inhaled COVID-19 treatment on Feb. 21.
BioNTech and Medigene announced a global agreement to develop T-cell immunotherapies against cancer. The three-year collaboration will focus on multiple solid tumor targets.
A new packaging and labeling manufacturing facility has derailed the potential approval of Malinckrodt’s investigational hepatorenal syndrome (HRS) treatment, terlipressin.
A new project uncovering genetic changes linked to damage following a heart attack could potentially pave the way for gene therapies to prevent long-term cell damage.
PRESS RELEASES